159 related articles for article (PubMed ID: 21385183)
1. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.
Schaub A; von Gunten S; Vogel M; Wymann S; Rüegsegger M; Stadler BM; Spycher M; Simon HU; Miescher S
Allergy; 2011 Aug; 66(8):1030-7. PubMed ID: 21385183
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.
von Gunten S; Vogel M; Schaub A; Stadler BM; Miescher S; Crocker PR; Simon HU
J Allergy Clin Immunol; 2007 Apr; 119(4):1005-11. PubMed ID: 17337295
[TBL] [Abstract][Full Text] [Related]
3. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
von Gunten S; Simon HU
Autoimmun Rev; 2008 Jun; 7(6):453-6. PubMed ID: 18558361
[TBL] [Abstract][Full Text] [Related]
4. Cell death modulation by intravenous immunoglobulin.
von Gunten S; Simon HU
J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180
[TBL] [Abstract][Full Text] [Related]
5. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
Altznauer F; von Gunten S; Späth P; Simon HU
J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880
[TBL] [Abstract][Full Text] [Related]
6. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies.
Vassilev TL; Bineva IL; Dietrich G; Kaveri SV; Kazatchkine MD
J Autoimmun; 1995 Jun; 8(3):405-13. PubMed ID: 7576001
[TBL] [Abstract][Full Text] [Related]
7. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
von Gunten S; Schaub A; Vogel M; Stadler BM; Miescher S; Simon HU
Blood; 2006 Dec; 108(13):4255-9. PubMed ID: 16902148
[TBL] [Abstract][Full Text] [Related]
8. Self-reactivity in the dimeric intravenous immunoglobulin fraction.
Schaub A; Wymann S; Heller M; Ghielmetti M; Beleznay Z; Stadler BM; Bolli R; Miescher S
Ann N Y Acad Sci; 2007 Sep; 1110():681-93. PubMed ID: 17911483
[TBL] [Abstract][Full Text] [Related]
9. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig.
Rossi F; Kazatchkine MD
J Immunol; 1989 Dec; 143(12):4104-9. PubMed ID: 2592768
[TBL] [Abstract][Full Text] [Related]
10. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies.
Dietrich G; Kazatchkine MD
J Clin Invest; 1990 Mar; 85(3):620-5. PubMed ID: 2312717
[TBL] [Abstract][Full Text] [Related]
11. What is the contents of the magic draft IVIg?
Seite JF; Shoenfeld Y; Youinou P; Hillion S
Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
[TBL] [Abstract][Full Text] [Related]
12. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin.
Reipert BM; Stellamor MT; Poell M; Ilas J; Sasgary M; Reipert S; Zimmermann K; Ehrlich H; Schwarz HP
Vox Sang; 2008 May; 94(4):334-41. PubMed ID: 18266779
[TBL] [Abstract][Full Text] [Related]
13. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases.
Blank M; Bashi T; Shoenfeld Y
Methods Mol Biol; 2014; 1060():353-61. PubMed ID: 24037850
[TBL] [Abstract][Full Text] [Related]
14. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.
Rossi F; Sultan Y; Kazatchkine MD
Clin Exp Immunol; 1988 Nov; 74(2):311-6. PubMed ID: 3147154
[TBL] [Abstract][Full Text] [Related]
15. Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss.
Konova E; Atanasova M; Stoykov S; Velkova A; Shoenfeld Y
J Autoimmun; 2007 Feb; 28(1):46-54. PubMed ID: 17178213
[TBL] [Abstract][Full Text] [Related]
16. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens.
Wymann S; Ghielmetti M; Schaub A; Baumann MJ; Stadler BM; Bolli R; Miescher SM
Mol Immunol; 2008 May; 45(9):2621-8. PubMed ID: 18280568
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.
Blank M; Anafi L; Zandman-Goddard G; Krause I; Goldman S; Shalev E; Cervera R; Font J; Fridkin M; Thiesen HJ; Shoenfeld Y
Int Immunol; 2007 Jul; 19(7):857-65. PubMed ID: 17576752
[TBL] [Abstract][Full Text] [Related]
18. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases.
Mouthon L; Kaveri S; Kazatchkine M
Transfus Sci; 1994 Dec; 15(4):393-408. PubMed ID: 10155557
[TBL] [Abstract][Full Text] [Related]
19. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
Jayne DR; Esnault VL; Lockwood CM
J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
[TBL] [Abstract][Full Text] [Related]
20. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block.
Routsias JG; Kyriakidis NC; Friedman DM; Llanos C; Clancy R; Moutsopoulos HM; Buyon J; Tzioufas AG
Arthritis Rheum; 2011 Sep; 63(9):2783-9. PubMed ID: 21618202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
